NO20013770L - Metoder og blandinger for å öke antall hvite blodceller - Google Patents

Metoder og blandinger for å öke antall hvite blodceller

Info

Publication number
NO20013770L
NO20013770L NO20013770A NO20013770A NO20013770L NO 20013770 L NO20013770 L NO 20013770L NO 20013770 A NO20013770 A NO 20013770A NO 20013770 A NO20013770 A NO 20013770A NO 20013770 L NO20013770 L NO 20013770L
Authority
NO
Norway
Prior art keywords
compositions
methods
increase
blood cells
white blood
Prior art date
Application number
NO20013770A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013770D0 (no
Inventor
Ronald Trevor Macfarland
Andrew W Millar
Gary James Bridger
Michael J Abrams
Geoffrey W Henson
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of NO20013770D0 publication Critical patent/NO20013770D0/no
Publication of NO20013770L publication Critical patent/NO20013770L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20013770A 1999-02-02 2001-08-01 Metoder og blandinger for å öke antall hvite blodceller NO20013770L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11825599P 1999-02-02 1999-02-02
PCT/CA2000/000104 WO2000045814A1 (fr) 1999-02-02 2000-02-02 Procedes et compositions pour ameliorer la numeration des globules blancs

Publications (2)

Publication Number Publication Date
NO20013770D0 NO20013770D0 (no) 2001-08-01
NO20013770L true NO20013770L (no) 2001-09-27

Family

ID=22377471

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013770A NO20013770L (no) 1999-02-02 2001-08-01 Metoder og blandinger for å öke antall hvite blodceller

Country Status (24)

Country Link
US (2) US6365583B1 (fr)
EP (1) EP1148875B1 (fr)
JP (2) JP4968868B2 (fr)
KR (1) KR100643553B1 (fr)
CN (1) CN1310642C (fr)
AP (1) AP1497A (fr)
AT (1) ATE268597T1 (fr)
AU (2) AU772979B2 (fr)
BR (1) BR0007924A (fr)
CA (1) CA2361587C (fr)
CZ (1) CZ20012698A3 (fr)
DE (1) DE60011391T2 (fr)
DK (1) DK1148875T3 (fr)
ES (1) ES2222174T3 (fr)
HK (1) HK1038319B (fr)
HU (1) HUP0200100A3 (fr)
IL (1) IL144400A (fr)
MX (1) MXPA01007801A (fr)
NO (1) NO20013770L (fr)
NZ (1) NZ513602A (fr)
PT (1) PT1148875E (fr)
SI (1) SI1148875T1 (fr)
TR (1) TR200102239T2 (fr)
WO (1) WO2000045814A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
WO2001044229A1 (fr) * 1999-12-17 2001-06-21 Anormed Inc. Recepteur de chemokine liant des composes heterocycliques
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
DK1317451T3 (da) * 2000-09-15 2006-12-18 Anormed Inc Kemokinreceptorbindende heterocykliske forbindelser
MXPA03002325A (es) * 2000-09-15 2003-06-24 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina.
MXPA03002772A (es) 2000-09-29 2003-07-28 Anormed Inc Procedimiento para la preparacion de poliaminas ciclicas que contienen nitrogeno en el anillo n-1 protegidos y productos de los mismos.
JP5137288B2 (ja) * 2001-07-31 2013-02-06 アノーメッド インコーポレイティド 前駆/幹細胞を動員する方法
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
PL372705A1 (en) * 2001-09-12 2005-07-25 Anormed Inc. Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
CN1596255A (zh) * 2001-12-21 2005-03-16 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
CA2520259A1 (fr) 2003-04-11 2004-10-28 Anormed Inc. Composes de liaison aux recepteurs de chimiokine cxcr4
CA2517077C (fr) * 2003-04-22 2013-03-12 Anormed Inc. Composes heterocycliques se liant aux recepteurs des chimiokines et qui presentent une efficacite accrue
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
WO2005059107A2 (fr) * 2003-12-11 2005-06-30 Anormed Inc. Composes de liaison aux recepteurs de la chemokine
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
EP1796716A4 (fr) * 2004-08-13 2010-09-08 Anormed Inc Combinaisons de chimiokines pour mobiliser des cellules progenitrices/souches
WO2006138350A2 (fr) * 2005-06-15 2006-12-28 Anormed Inc. Composes de liaison au recepteur de la chimiokine
EP1924265A4 (fr) * 2005-08-16 2010-06-02 Genzyme Corp Composes se liant aux recepteurs de chimiokine
AU2006340074A1 (en) * 2006-02-24 2007-09-20 Genzyme Corporation Methods for increasing blood flow and/or promoting tissue regeneration
AU2007281090A1 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
MX2009001445A (es) * 2006-08-07 2009-02-18 Genzyme Corp Terapia de combinacion.
WO2008075370A2 (fr) * 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. Analogues peptidiques de t-140 présentant une activité superagoniste par rapport à cxcr4 destinés à une cancérothérapie
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
CA2807552A1 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucleiques modifies et leurs procedes d'utilisation
US20150030561A1 (en) * 2011-05-16 2015-01-29 Genzyme Corp. Use of CXCR4 Antagonists
WO2013160895A1 (fr) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides et leur utilisation dans le traitement du cancer du poumon à grandes cellules
EP3744340A3 (fr) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions et procédés pour le traitement du cancer
WO2017106332A1 (fr) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
HUE060517T2 (hu) 2015-12-22 2023-03-28 X4 Pharmaceuticals Inc Immunhiányos betegség kezelésére szolgáló eljárások
US10993985B2 (en) 2016-02-23 2021-05-04 BioLmeRx Ltd. Methods of treating acute myeloid leukemia
WO2017177230A1 (fr) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
WO2017223229A1 (fr) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
CA3027500A1 (fr) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN109187337A (zh) * 2018-09-10 2019-01-11 南京工业职业技术学院 一种筛选强韧性FeAl晶界的方法
JP2023517956A (ja) 2020-03-10 2023-04-27 エックス4 ファーマシューティカルズ, インコーポレイテッド 好中球減少症を処置する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
WO2000028987A1 (fr) * 1998-11-17 2000-05-25 Smithkline Beecham Corporation Traitements de la thromcocytopenie

Also Published As

Publication number Publication date
US6670354B2 (en) 2003-12-30
TR200102239T2 (tr) 2002-01-21
IL144400A (en) 2010-05-17
EP1148875B1 (fr) 2004-06-09
AU772979B2 (en) 2004-05-13
WO2000045814A1 (fr) 2000-08-10
NZ513602A (en) 2003-10-31
AP1497A (en) 2005-11-20
DK1148875T3 (da) 2004-10-18
ES2222174T3 (es) 2005-02-01
AP2001002221A0 (en) 2001-09-30
DE60011391D1 (de) 2004-07-15
CA2361587A1 (fr) 2000-08-10
CA2361587C (fr) 2010-04-20
HK1038319A1 (en) 2002-03-15
KR20010101896A (ko) 2001-11-15
JP4968868B2 (ja) 2012-07-04
CN1310642C (zh) 2007-04-18
CZ20012698A3 (cs) 2002-03-13
AU2004203847A1 (en) 2004-09-09
JP2011088937A (ja) 2011-05-06
BR0007924A (pt) 2001-11-06
PT1148875E (pt) 2004-10-29
HK1038319B (en) 2005-03-18
CN1338933A (zh) 2002-03-06
HUP0200100A3 (en) 2004-07-28
IL144400A0 (en) 2002-05-23
HUP0200100A2 (hu) 2002-05-29
KR100643553B1 (ko) 2006-11-10
NO20013770D0 (no) 2001-08-01
EP1148875A1 (fr) 2001-10-31
JP2002536329A (ja) 2002-10-29
AU2527800A (en) 2000-08-25
MXPA01007801A (es) 2003-06-04
US6365583B1 (en) 2002-04-02
SI1148875T1 (en) 2004-12-31
DE60011391T2 (de) 2005-07-14
US20020058653A1 (en) 2002-05-16
ATE268597T1 (de) 2004-06-15
AU2004203847B2 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
NO20013770D0 (no) Metoder og blandinger for å öke antall hvite blodceller
ATE357459T1 (de) Antikörper gegen mensliches il-12
NO20013393D0 (no) Brönnsementeringsfremgangsmåter og sammensetninger
NO20000847L (no) Elastiske brønnsementsammensetninger og fremgangsmÕter
DE60024988D1 (de) Herstellung von therapeutischem mikroschaum
IS5619A (is) (4-Arýlsúlfónýlamínó) -tetrahýdrópýran-4-karboxýlsýru hýdroxamíð
NO20000011D0 (no) Skumdempersammensetninger og fremgangsmåter
DE69927969D1 (de) Kontrollierte freisetzung von liponsäure
DE60001676D1 (de) Silikongelzusammensetzung und daraus hergestelltes Silikongel
ID29031A (id) Piperidin sebagai modulator ccr5
ITMI991754A0 (it) Composizioni cosmetiche
AR023440A1 (es) Composiciones antitranspirantes
DE69933200D1 (de) Kombinierte impfstoffzusammensetzungen
ATE258418T1 (de) Shampoozusammensetzungen
ID27346A (id) Peralatan pengenal suara
DE60019960D1 (de) Herstellung von isobutencopolymere
DE60025624D1 (de) Farbstabile polyarylat enthaltende zusammensetzungen
ID30226A (id) Komposisi penat rambut
ID27522A (id) Fasilitas untuk bermain
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
ID17482A (id) Komposisi untuk meningkatkan kesehatan mulut
DE60030062D1 (de) Verringerung des verhältnisses spitzen- zu durchschnittsleistung bei mehrträgerübertragung
DK1228026T3 (da) 15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse
NO20005322L (no) Fremgangsmåte for å öke effektiviteten av handel
DE60024095D1 (de) Wasserenthärtungs- und waschmittelzusammensetzungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application